Atlas Trials

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Clinical trial NCT02241785 · TERMINATED

Trial details

NCT number
NCT02241785
Sponsor
Biogen
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Relapsing Multiple Sclerosis
Start date
2014-09-30
Primary completion
2016-05-02
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.